At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses new data that support earlier treatment of patients with mantle cell lymphoma (MCL), including the results of an investigation of a bortezomib-based regimen as frontline therapy for patients with newly diagnosed MCL.
Therapy for newly diagnosed patients with mantle cell lymphoma
21st August 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?